Literature DB >> 9061579

Cell-mediated immunity in HIV seronegative patients recovered from Cryptococcus neoformans var. gattii meningitis.

R A Seaton1, S Naraqi, J P Wembri, D A Warrell.   

Abstract

Cell-mediated immunity was assessed in 37 HIV seronegative healthy patients cured of Cryptococcus neoformans var. gattii meningitis and compared with matched controls using a multitest device which simultaneously injects seven standardized common antigens intradermally. Responses in patients and controls were similar: however, male patients had significantly higher compound (average) scores than controls (P = 0.041). Male scores were higher than female scores in both patient (P = 0.002) and control (P = 0.017) groups. In eight patients with acute cryptococcal meningitis, seven were anergic to challenge with 5 IU of tuberculin on admission. Two of these patients had positive reactions after treatment. Three of four patients tested prior to treatment with the multitest device were anergic to all seven antigens but all three survivors showed improved responsiveness following cure. These data suggest that patients are immunosuppressed on presentation (due to overwhelming var. gattii infection) but that following cure, cell-mediated immunity improves to its premorbid state. A transient state of immunosuppression prior to the development of the disease cannot be excluded.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9061579

Source DB:  PubMed          Journal:  J Med Vet Mycol        ISSN: 0268-1218


  2 in total

1.  Temperature-sensitive strain of Cryptococcus neoformans producing hyphal elements in a feline nasal granuloma.

Authors:  D A Bemis; D J Krahwinkel; L A Bowman; P Mondon; K J Kwon-Chung
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

2.  Effect of virulence factors on the photodynamic inactivation of Cryptococcus neoformans.

Authors:  Renato A Prates; Beth Burgwyn Fuchs; Kazue Mizuno; Qurat Naqvi; Ilka T Kato; Martha S Ribeiro; Eleftherios Mylonakis; George P Tegos; Michael R Hamblin
Journal:  PLoS One       Date:  2013-01-18       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.